Watershed Asset Management L.L.C. bought a new position in Humana Inc. (NYSE:HUM – Free Report) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 2,735 shares of the insurance provider’s stock, valued at approximately $474,000.
Several other large investors have also added to or reduced their stakes in HUM. Hartford Funds Management Co LLC bought a new stake in Humana during the 1st quarter worth approximately $419,000. Calamos Wealth Management LLC bought a new position in shares of Humana in the first quarter valued at approximately $301,000. Calamos Advisors LLC boosted its position in shares of Humana by 4.9% during the first quarter. Calamos Advisors LLC now owns 37,245 shares of the insurance provider’s stock valued at $6,458,000 after buying an additional 1,735 shares during the last quarter. AMF Tjanstepension AB boosted its position in shares of Humana by 2.9% during the first quarter. AMF Tjanstepension AB now owns 155,989 shares of the insurance provider’s stock valued at $27,047,000 after buying an additional 4,433 shares during the last quarter. Finally, J. Safra Sarasin Holding AG grew its holdings in Humana by 41.0% during the first quarter. J. Safra Sarasin Holding AG now owns 4,773 shares of the insurance provider’s stock worth $827,000 after buying an additional 1,389 shares in the last quarter. Institutional investors own 92.38% of the company’s stock.
Humana Stock Performance
Shares of Humana stock opened at $400.51 on Friday. The business’s fifty day simple moving average is $354.03 and its 200 day simple moving average is $260.19. The company has a current ratio of 1.77, a quick ratio of 1.77 and a debt-to-equity ratio of 0.66. Humana Inc. has a 12 month low of $163.11 and a 12 month high of $428.88. The firm has a market capitalization of $48.09 billion, a P/E ratio of 42.84, a price-to-earnings-growth ratio of 2.09 and a beta of 0.71.
Analyst Ratings Changes
HUM has been the subject of a number of analyst reports. Bank of America increased their price target on Humana from $340.00 to $380.00 and gave the company a “neutral” rating in a research report on Wednesday, June 24th. Sanford C. Bernstein reiterated an “outperform” rating and issued a $425.00 target price on shares of Humana in a research note on Wednesday, June 3rd. William Blair started coverage on shares of Humana in a report on Wednesday, May 20th. They issued an “outperform” rating for the company. Zacks Research raised shares of Humana from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 13th. Finally, Mizuho boosted their price target on shares of Humana from $335.00 to $390.00 and gave the stock an “outperform” rating in a report on Monday, June 8th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, fifteen have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $325.87.
Read Our Latest Stock Analysis on Humana
Humana Company Profile
Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.
In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.
Featured Articles
- Five stocks we like better than Humana
- AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector
- Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth
- TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident
- GE Aerospace Faces a Prove-It Moment in Q2 Earnings
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.
